AI Article Synopsis
- The study aimed to understand the clinical features and genetic causes of a child with Turner syndrome (TS) who experienced rapid puberty progression, collecting data and performing genetic analysis.
- The 13-year-old patient exhibited early signs of puberty and had a specific karyotype (46,X,i(X)(q10)), alongside physical characteristics like short stature and multiple nevi.
- Literature review revealed similar cases with common traits of short stature and chromosomal mosaicisms, highlighting the unique clinical manifestations associated with Turner syndrome and rapid puberty development.*
Article Abstract
Objective: To investigate the clinical features and genetic etiology of a case of Turner syndrome (TS) with rapidly progressive puberty.
Methods: A child who had presented at the Pediatric Endocrinology Clinic of the Shenzhen People's Hospital on January 19, 2022 was selected as the study subject. Clinical data of the child were collected. Peripheral blood sample of the child was subjected to chromosomal microarray analysis (CMA) and multiple ligation-dependent probe amplification (MLPA). Previous studies related to TS with rapidly progressive puberty were retrieved from the CNKI, Wanfang Data Knowledge Service Platform, Boku, CBMdisc and PubMed databases with Turner syndrome and rapidly progressive puberty as the keywords. The duration for literature retrieval was set from November 9, 2021 to May 31, 2022. The clinical characteristics and karyotypes of the children were summarized.
Results: The child was a 13-year-and-2-month-old female. She was found to have breast development at 9, short stature at 10, and menarche at 11. At 13, she was found to have a 46,X,i(X)(q10) karyotype. At the time of admission, she had a height of 143.5 cm (< P3), with 6 ~ 8 nevi over her face and right clavicle. She also had bilateral simian creases but no saddle nasal bridge, neck webbing, cubitus valgus, shield chest or widened breast distance. She had menstruated for over 2 years, and her bone age has reached 15.6 years. CMA revealed that she had a 58.06 Mb deletion in the Xp22.33p11.1 region and a 94.49 Mb duplication in the Xp11.1q28 region. MLPA has confirmed monosomy Xp and trisomy Xq. A total of 13 reports were retrieved from the CNKI, Wanfang Data Knowledge Service Platform, Boku, CBMdisc and PubMed databases, which had included 14 similar cases. Analysis of the 15 children suggested that their main clinical manifestations have included short stature and growth retardation, and their chromosomal karyotypes were mainly mosaicisms.
Conclusion: The main clinical manifestations of TS with rapidly progressive puberty are short stature and growth retardation. Deletion in the Xp22.33p11.1 and duplication in the Xp11.1q28 probably underlay the TS with rapid progression in this child, which has provided a reference for clinical diagnosis and genetic counselling for her.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3760/cma.j.cn511374-20220721-00484 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development and Selection of Candidate Monoclonal Antibodies for the Detection of Clostridium botulinum Neurotoxin Serotype B Light Chain.
Protein Expr Purif
January 2025
Institute of Tropical Medicine, Joint Vietnam-Russia Tropical Science and Technology Research Center.
Botulinum neurotoxin, produced by the bacterium Clostridium botulinum, causes botulism, a severe, rapidly progressing, and potentially fatal condition. Swift detection of the toxin and timely administration of antitoxin antibodies are critical for effective treatment. The current standard for Botulinum toxin testing is the mouse lethality assay, but this method is time-consuming and requires live animals.
View Article and Find Full Text PDFA non-purine inhibitor of xanthine oxidoreductase mitigates adenosine triphosphate degradation under hypoxic conditions in mouse brain.
Brain Res
January 2025
Department of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo, Japan. Electronic address:
The brain is an organ that consumes a substantial amount of oxygen, and a reduction in oxygen concentration can rapidly lead to significant and irreversible brain injury. The progression of brain injury during hypoxia involves the depletion of intracellular adenosine triphosphate (ATP) due to decreased oxidative phosphorylation in the inner mitochondrial membrane. Allopurinol is a purine analog inhibitor of xanthine oxidoreductase that protects against hypoxic/ischemic brain injury; however, its underlying mechanism of action remains unclear.
View Article and Find Full Text PDFMPIC: Exploring alternative approach to standard convolution in deep neural networks.
Neural Netw
December 2024
Institute of Automation, Chinese Academy of Sciences, MAIS, Beijing, 100190, China; University of Chinese Academy of Sciences, Beijing, 101408, China.
In the rapidly evolving field of deep learning, Convolutional Neural Networks (CNNs) retain their unique strengths and applicability in processing grid-structured data such as images, despite the surge of Transformer architectures. This paper explores alternatives to the standard convolution, with the objective of augmenting its feature extraction prowess while maintaining a similar parameter count. We propose innovative solutions targeting depthwise separable convolution and standard convolution, culminating in our Multi-scale Progressive Inference Convolution (MPIC).
View Article and Find Full Text PDFChampioning fundamental discovery research: quality over quantity.
FEBS J
January 2025
Department of Structural Biology, University of Pittsburgh School of Medicine, PA, USA.
Rapidly emerging technologies, such as generative AI tools, have already had a reverberating impact on science and society. The notion that such tools could be entrusted with 'mapping' the trajectory of scientific discovery toward immediate measurable applications, however, is problematic. I instead argue that curiosity-driven fundamental research should remain the base upon which to build progress.
View Article and Find Full Text PDFOptimizing combination targeted immunotoxin therapy: Insights from HER2 and EpCAM expression profiles.
Biochem Biophys Res Commun
December 2024
Moscow Center for Advanced Studies, Kulakova Str. 20, 123592, Moscow, Russia; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 16/10 Miklukho-Maklaya St., 117997, Moscow, Russia. Electronic address:
Molecular targeted cancer therapy is a rapidly developing field, driving progress toward greater treatment efficacy. However, targeted monotherapy often fails due to the development of multidrug resistance in tumors. The combination of multiple targeted agents emerges as a possible solution to enhance treatment outcomes by activating different signaling pathways.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!